Teva Pharmaceutical Industries Ltd. reported first‑quarter 2026 results that exceeded expectations, with revenue of $3.982 billion and non‑GAAP diluted earnings per share of $0.53, beating the consensus estimate of $0.48. Operating income rose to $652 million, a 25% increase from $519 million in Q1 2025, while free cash flow climbed to $188 million from $107 million a year earlier.
Revenue grew 2% in U.S. dollars from the same period last year, driven by a 41% year‑over‑year increase in the company’s innovative portfolio—AUSTEDO, AJOVY, and UZEDY—which generated $838 million in local currency. Segment‑level data show U.S. revenue at $1.53 billion, Europe at $1.34 billion, and other international markets at $1.10 billion, underscoring the shift toward higher‑margin specialty products.
Gross margin expansion was a key driver of operating income growth. The U.S. segment gross margin increased to 67.7% in Q1 2026 from 65.9% in Q1 2025, while the overall margin improved as the mix shifted toward the higher‑margin innovative brands. This margin lift, combined with cost discipline, enabled the 25% rise in operating income.
Management reaffirmed its 2026 full‑year guidance, maintaining sales outlook of $16.4 billion to $16.8 billion and adjusted EPS range of $2.57 to $2.77. The company noted that the acquisition of Emalex Biosciences, announced earlier in the year, is expected to lower the 2026 non‑GAAP EPS outlook by $0.66, bringing it to $1.91–$2.11, but the guidance still reflects confidence in the company’s growth trajectory.
Headwinds remain in the generics segment, particularly from competition in lenalidomide capsules, but the company’s biosimilar pipeline and new generic launches are bolstering its foundational business. Teva’s balance‑sheet repair continues, with net debt‑to‑EBITDA falling to 2.5x from 3.1x in Q2 2025, and the company is on track to reach a 2.0x target by 2027.
The market reacted strongly, with the stock surging 7.5% in pre‑market trading. Analysts cited the earnings and revenue beat, the robust growth of the innovative portfolio, the reaffirmed revenue guidance, and the strategic acquisition of Emalex Biosciences as the primary drivers of the positive reaction.
Richard Francis, Teva’s President and CEO, said, “Our first quarter results are driven by strong growth in our key innovative products, continuing to shift Teva's portfolio mix and support improvement in its financial profile. These results reflect disciplined execution of our Pivot to Growth strategy, and our focus remains unchanged: growing our innovative portfolio, improving margins and advancing key value‑unlocking portfolio milestones expected during 2026 and beyond.” He added, “In parallel, biosimilars are becoming an increasingly important growth contributor, alongside new product launches in generics, reinforcing the foundational importance of Teva's generic powerhouse.”
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.